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Abstract
One of the most prevalent complaints of individuals with mid-stage and ad-
vanced Parkinson’s disease (PD) is the fluctuating response to their medication
(i.e., ON state with maximum benefit from medication and OFF state with
no benefit from medication). In order to address these motor fluctuations, the
patients go through periodic clinical examination where the treating physician
reviews the patients’ self-report about duration in different medication states
and optimize therapy accordingly. Unfortunately, the patients’ self-report can
be unreliable and suffer from recall bias. There is a need to a technology-based
system that can provide objective measures about the duration in different med-
ication states that can be used by the treating physician to successfully adjust
the therapy. In this paper, we developed a medication state detection algorithm
to detect medication states using two wearable motion sensors. A series of sig-
nificant features are extracted from the motion data and used in a classifier
that is based on a support vector machine with fuzzy labeling. The developed
algorithm is evaluated using a dataset with 19 PD subjects and a total dura-
tion of 1,052.24 minutes (17.54 hours). The algorithm resulted in an average
classification accuracy of 90.5%, sensitivity of 94.2%, and specificity of 85.4%.
Keywords: Parkinson’s Disease, Wearable Data Analysis, Feature Extraction
and Classification, Support Vector Machine
1. Introduction
Parkinson’s disease (PD) is one of the most common chronic progressive
neurological disorders, affecting over half a million Americans and resulting in
over $20 billion in direct and indirect costs a year, which is predicted to double
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by 2040. [1]. PD leads to devastating chronic complications including observ-
able motor symptoms such as tremor, bradykinesia/akinesia (reduced speed
and quantity of spontaneous movement), and gait/balance impairment lead-
ing to falls, as well as non-motor symptoms such as cognitive impairment and
sleep disorders. Levodopa is the most common medication used to improve mo-
tor impairments in subjects with PD. Unfortunately, prolonged treatment with
Levodopa causes troubling motor fluctuations [2]. Almost all patients under the
age of 40 will develop motor complications after 6 years from the introduction of
Levodopa [3]. These complications result in frequent fluctuations of "response
to treatment intervention" between "ON" state with maximum benefit from
Levodopa and "OFF" state with least benefit from Levodopa, and are a major
focus of PD management [4]. The current protocol to address these motor fluc-
tuations involves adjusting therapy, e.g., medication frequency and dosage or
Deep Brain Stimulation (DBS) parameters, according to durations in medica-
tion ON and OFF states that are obtained from patient’s self-reports. Patient
self-reports require extensive patient education. Even then, self-reports can be
unreliable and suffer from recall bias [5], resulting in frequent clinical exami-
nations to adjust therapy. Unfortunately, these frequent clinical examinations
result in an over 50% increase in just annual direct costs and may not be practi-
cal in rural areas where neurologists are not widely available. Technology-based
assessments of patients’ response to therapy, using wearable sensors, holds great
promise in providing objective measures during subjects’ daily, free-living con-
dition that can be used by the treating physician to adjust therapy [6]. In this
work, our objective is to develop a sensor-based assessment system that can de-
tect patients’ responses to treatment interventions (i.e., duration in medication
ON and OFF states) that are obtained from patients’ self-reports. The devel-
opment of a sensor-based assessment system that can passively detect clinically
important information on patients’ duration in medication ON and OFF states,
from natural environment of individuals, will play a significant role in yield-
ing improved PD therapy adjustment strategies to reduce complicated motor
fluctuations and associated healthcare costs without the need for less reliable
patient self-reports or frequent clinical examinations.
The wide availability of wearable inertial sensors, combined with machine
learning algorithms, has led to the development of algorithms for detection of
medication ON and OFF states in subjects with PD. However, the existing
approaches do not fully address the need for clinically actionable information as
required for the therapy adjustments. First, some approaches obtained accurate
results if the detection was performed for some specific activity, such as walking
[7, 8, 9] or non-walking [10]. This is problematic as those methods can identify
medication states only during those specific activities and are unable to provide
a continuous monitoring of the subjects as needed for detection of clinically
important information about duration in different medication states. Second,
some approaches trade accuracy for continuous monitoring [11, 12, 13, 14, 15],
or have to use five to seven sensors at different parts of the body in order
to provide acceptable accuracy. As a result, the condition under which the
subjects need to use the device is very impractical with too many sensors to
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wear. Third, these systems are based on a "one-size-fits-all" approach and
do not consider inter-subject variability. For example, one subject’s ON state
could be another subject’s OFF state depending on the disease stage and each
individual’s variability with respect to somatotopy (body parts are impaired),
phenomenology (different motor impairments are present), and severity (e.g.
one subject’s best movement speed may correspond to a less advanced subject’s
worst movement speed). However, the underlying algorithms of these systems
are modeled using data from a group of well-characterized subjects and are used
on new subjects [16]. Hence, they have limited generalizability and still require
additional clinical examinations be performed to customize their report for a
new subject.
In this work, we developed and validated through experiments an algorithm
to automatically detect medication ON and OFF states. Our approach is novel
in that it is customized to each subject rather than a "one-size-fits-all" ap-
proach, and can continuously detect and report medication ON and OFF states
as subjects perform different daily routine activities. To attain our objectives,
we tested the hypothesis that the medication ON and OFF patterns in two
wearable sensor data can be modeled and identified for every individual, when
compared to the gold-standard medication ON and OFF states reported by a
neurologist. The population of interest in this study is PD patients with motor
fluctuation who go through follow-up visits as frequently as every 6 months.
There will be multiple adjustments in the medications, which are heavily based
on the subjects’ self-report. Hence, patients would benefit most from an au-
tomated and user-friendly system that is trained in their first visit, and then
readily used to detect their response to medication (durations in ON/OFF med-
ication states) on a continuous basis and provide these objective measures that
can be used by the treating physician to adjust therapy.
2. Methods
We developed a new approach to detect medication ON/OFF states of PD
subjects using data from two triaxial gyroscope sensors as patients performed a
variety of daily-life activities. The approach consists of a feature extraction and
selection stage, which represents each segmented window as a set of features,
and a classifier based on a support vector machine (SVM) with fuzzy labeling.
The details of the data collection and processing, as well as feature extraction
and training the classifier, are explained in this section.
2.1. Dataset
A total of 19 PD subjects were selected in this study (see Table 1 for subject
demographics). The recording system (Figure 1(a)) was based on a KinetiSense
motion sensor unit (Great Lakes NeuroTechnologies Inc., Cleveland, OH) con-
sisting of a triaxial accelerometer and triaxial gyroscope with 128 Hz sampling
rate. Two of these units were mounted on the back and front of the most af-
fected wrist and ankle, respectively, as shown in Figure 1(b). The study was
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approved by the institutional review board, and all patients provided written
informed consent. The dataset was collected under the protocol in Refs. [17, 18].
All the participants were asked to stop their medication the night before the
scheduled examination and started the experiment in their medication OFF
state. First, they were asked to perform the following seven daily living activ-
ities: resting, walking, drinking, dressing, hair brushing, unpacking groceries,
and cutting food. Next, the subjects took their normal anti-parkinsonian medi-
cations and performed the same daily activities again. Later, when the subjects
were in their ON state, confirmed by a neurologist’s direct observation, they
were asked to cycle through all the stations one more time. Concurrently, the
clinical examinations were performed by a neurologist to measure and record pa-
tients’ Unified Parkinson’s Disease Rating Scale (UPDRS) [4] and tremor scores
during OFF and ON states. The UPDRS is composed of four subscales: Part
1 and 2 considers non-motor symptoms and motor experiences of daily living,
respectively. Part 3 measures severity of motor complications and is performed
by clinical examinations, and part 4 measures motor fluctuation and dyskinesia
(abnormal involuntary movements) complications. Tremor score for the more
affected hand/foot was reported with the following ratings: 0 = absent. 1 =
possible rest tremor. 2 = slight and infrequently present. 3 = mild in amplitude
and persistent, or moderate in amplitude, but only intermittently present. 4 =
moderate in amplitude and present most of the time. 5 = marked in amplitude
and present most of the time.
Table 1: The Subject Demographics. AC-UPDRS stands for average change between the
ON- and OFF-state UPDRS, and LEDD for Levodopa Equivalent Daily Dose. Values are
presented as n, mean ± STD and/or [range].
Number of Subjects 19 OFF UPDRS 31 ± 13 [12-60]
Age [yr-yr] [42-77] ON UPDRS 14 ± 8 [4-35]
Sex (M, F) 14, 5 AC-UPDRS 14.4±7.9
Disease Duration (y) 9.2 ± 3.8 OFF Tremor (Hand, Foot) 0.68 ± 1.11, 0.53 ± 0.84
LEDD (mg) 1282.5±459.8 ON Tremor (Hand, Foot) 0.05 ± 0.23, 0.00 ± 0.00
2.2. Data Preprocessing
The KinetiSense motion sensors used in the collection provided two motion
data types: gyroscope and accelerometer. We used the gyroscope data as is
less affected by vibration and mechanical noise than an accelerometer and is
expected to better reflect limb rotations that occur during tremor and other
PD motor symptoms due to absence of gravity [17, 19, 20]. The gyroscope
signals were preprocessed by applying a bandpass FIR filter with a pass fre-
quency between (0.5-15Hz) on the three axes of the recorded signal from each
sensor to eliminate low and high-frequency noises. Next, the filtered data was
segmented into 5-second-long signals with 4-second overlaps between each seg-
ments as shown to be a suitable signal duration to detect bradykinesia and
tremor [21].
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(a) (b)
Back Front
Figure 1: (a) KinetiSense motion sensor unit. (b) The locations of the wearable sensors.
Table 2: The average duration of the data and number of segments that were used for training
and testing the algorithm. Values are presented as mean ± SD.
Training Testing
OFF ON OFF ON
Minutes 4.08 ± 2.61 3.80 ± 2.68 37.00 ± 47.79 15.77 ± 13.30
Segments 223 ± 149 209 ± 156 2,203 ± 2,880 902 ± 824
Activities part of walking, drinking,resting, and dressing
remaining of walking, drinking,
resting, and dressing
+
hair brushing, unpacking groceries,
and cutting food
part of walking, drinking,
resting, and dressing
remaining of walking, drinking,
resting, and dressing
+
hair brushing, unpacking groceries,
and cutting food
2.3. Selecting Training and Testing Data
In a real-life scenario, the developed algorithm will be trained during a pa-
tient’s first visit. Then, it will be used to detect the response to medication
(ON/OFF medication states) on a continuous basis and report objective in-
formation about the duration in ON and OFF states to the treating neurol-
ogist for remote medication adjustments. We selected the training data such
that it is feasible to collect during a routine clinical assessment, and does not
cause additional burden on the subjects or their treating physicians. Hence,
the training data was selected to be short in duration and also from the ac-
tivities that can be performed in an office setting (i.e., ambulation, drinking,
arm resting, and dressing) and are normally performed as part of the routine
assessments in Parkinson’s disease (CAPSIT-PD) and Unified Dyskinesia Rat-
ing Scale (UDysRS) [22]. The average duration of the ON and OFF training
and testing data and the number of analyzed segments are reported in Table 2.
Note that there is no overlap between the training and testing data.
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2.4. Feature Extraction
The total number of extracted features for every window, before any feature
selection, was 69. Twenty-two of these features were extracted from each X,
Y, and Z signals (resulting in a total of 66 for all the three axes) and three
features were jointly extracted from the three axes’ signals. These extracted
features were concatenated into one feature vector to represent the data. An
alternative approach would be extracting the features from the magnitude sig-
nal; however, this method is unable to retain the directional information of the
subject’s movement. Table 3 lists the extracted features from a segmented win-
dow, {Wi}i=1:NTr , where NTr is the number of windows in a subject’s training
data. The signal power of A-B Hz band (Features 1-3) was calculated as the
summation of the signal powers of the A-B Hz band in the Fourier Domain.
The spectral entropy (Feature 5) of the spectrum {Wi(f)}i=1:NTr represented
the complexity in each window. The dominant frequency feature (Feature 7)
was the dominant harmony of the power spectral density as PD subjects in the
OFF state present lower dominant frequency with lower power than in their
ON state [23]. Average jerk (Feature 10) was the mean of the second derivative
of angular velocity to represent the rate of change. Temporal Shannon entropy
(Feature 20) represented the complexity and randomness in the signal as defined
below:
{HWi}i=1:NTr = −
∑
b∈Bi
(p(b) ∗ log2(p(b))) (1)
where Bi is a histogram bin set in the range (-400,400) with 200 steps for Wi,
which are found to be effective in this work, and p(b) is the bin b probability
in Bi. The range of the bin set comes from the 75th and 25th percentile of the
angular velocity reading. Gini Index (Feature 21) with a value between 0 and 1
was extracted to measure the moving complexity and was calculated as follows:
{GWi}i=1:NTr = 1−
∑
b∈Bi
p(b)2 (2)
Sample entropy (Feature 22) was extracted to measure dissimilarity in a
given window (Wi). It was calculated by first segmenting Wi into vectors of
length m and m+1 defined as Xm(τ) = {Wi(τ),Wi(τ+1),Wi(τ+2), ...,Wi(τ+
m−1)} where τ is the lag between the segments. Second, the Chebyshev distance
was calculated between all the vectors of length m+1 (d1) and of length m (d2).
If any of these distances was less than a tolerance r, then their corresponding
counter M1 and M2 was increased by one, respectively, as shown below:
M1 =
∑NS−m−1
j=1
∑NS−m−1
k={j+1|d1} 1 (3)
M2 =
∑NS−m−1
j=1
∑NS−m−1
k={j+1|d2} 1 (4)
where d1 = d[Xm+1(j), Xm+1(k)] < r, d2 = d[Xm(j), Xm(k)] < r, and d[., .]
is the Chebyshev distance. In this work, m and r were set to two and 20%
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of the standard deviation of the gyroscope signal, respectively. Finally, sample
entropy was computed as follows:
{SEWi}i=1:NW = − log
M1
M2
(5)
Cross-correlation feature (ρWA1
i
WA2
i
) (Features 23-25) was computed to quan-
tify symmetry between the A1 and A2 axes of the recorded gyroscope signal.
Since PD subjects tend to bend their limbs in the ON state, these features were
designed to use symmetry between different axes to differentiate between the
ON and OFF states.
2.4.1. Selection of Significant Features:
For every training and testing set of data, we applied a statistical analysis ap-
proach to the features from the training data to select the features that provide a
high discrimination between the ON and OFF medication states. First, the nor-
mality of distribution of every feature was assessed using the Anderson-Darling
test. Next, the statistical significance of the normally distributed features was
tested using unpaired t-test [29], and for the non-normally distributed features
the Wilcoxon rank sum was used. Features with 5% significance level (i.e.,
p-value < 0.05) between the ON verses OFF medication states were selected.
The selected features were used in the training and testing of the classifier as
explained in the next section.
2.5. SVM Classification With Fuzzy Labeling
Our prior analysis [24] showed that the support vector machine (SVM) was
suitable for modeling ON verses OFF medication states and outperformed the
well-known clustering classification methods. This observation was in agreement
with the study performed in Ref. [12]. Hence, in this work, the well-known SVM
approach was employed. The algorithm consists of a training and a testing stage,
where the former adjusts the SVM parameters based on the training data and
the latter tests the trained SVM model on the testing data.
2.5.1. Training:
We used the recursive feature elimination (REF) method to jointly select
features and train SVM hyperparameters [30]. REF selects features via a greedy
backward selection: it trains the SVM hyperparameters, and obtains a feature
weight vector based on minimizing generalization bounds of the leave-one-out
cross validation, using a gradient descent approach. It then removes the feature
with the smallest returned absolute-value weight. This process is repeated until
a maximum classification accuracy is achieved. We used the Feature Selection
Library MATLAB Toolbox [31] to perform the above feature selection process
and train the SVM hyperparameters (i.e., linear or RBF kernel, cost parameter
(c ∈ 2{−2,...,2}), and gamma parameter (γ ∈ 2{−4,...,4})).
Classification Certainty (P ): It is known that SVM does not provide any pos-
terior probability that can represent the model classification certainty. Platt et
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Table 3: List of extracted features
Feature # Feature Description
1 Signal power of 1-4 Hz band [9, 24]
2 Signal power of 4-6 Hz band [24, 25]
3 Signal power of 0.5-15 Hz band [24]
4 Percentage of the powers for frequencies > 4Hz [10]
5 Spectral entropy (SH) [20]
6 Peak in the power spectral density [23, 17]
7 Dominant frequency [23]
8 Second peak in the power spectral density
9 Secondary frequency associated with the second peak
10 Average jerk [24]
11 Standard deviation (σ) [12, 20, 24]
12 Peak-to-peak in the recorded signal
13 Mean value for each window (µWi) [26]
14 Number of autocorrelation peaks
15 Sum of autocorrelation peaks
16 Lag of the first autocorrelation peak [27]
17 First autocorrelation peak (excluding the peak at the origin)
18 Skewness (γ1) [26]
19 Kurtosis (k)[26]
20 Temporal Shannon entropy [20, 24]
21 Gini Index [24]
22 Sample entropy (SE) [28]
23 Cross-correlation (ρWX
i
WY
i
) between X and Y axes
24 Cross-correlation (ρWX
i
WZ
i
) between X and Z axes
25 Cross-correlation (ρWY
i
WZ
i
) between Y and Z axes
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al. [32] proposed a parametric form of sigmoid to provide a measure of pos-
terior probability for SVM that measures the confidence of the trained SVM
model in detecting the medication state of each window. This approach uses
a parametric model according to Eq. 6 to fit posterior P (F = 1|D) where F
indicates feature vectors, D represents the SVM decision values, and 1 refers to
the class labels being medication "ON state". The parameters A and B are fit
using maximum likelihood estimation from a union of n-fold sets of D values
from the training data. Each of these sets were obtained after training a SVM
model on (n-1) fold of the training data and validating them on the remaining
fold to find D values for each feature vector in that fold. The union of all D
values as a result of the cross-validation on the training data were used as the
training set of the sigmoid. Two scalar parameters (A and B) were estimated
by minimizing a negative log likelihood based on the ground truth labels and
the training decision values, D1×NTr [32]. We determined these values, D1×NTr ,
from the training data based on an 4-fold cross-validation of the four activities
in the training data. The estimated parameters (A and B) were then used in
Eqs. 6 and 7 to provide a measure of the classification certainty 0 ≤ Pn ≤ 1 of
a classification decision value Mn.
{Pn}{n=1:NTe|Mn>0} = 11+eA×Mn+B (6)
{Pn}{n=1:NTe|Mn<0} = e
A×Mn+B
1+eA×Mn+B (7)
where a higher value of Pn indicates a higher certainty in the classification
decision value. Hence, the decision values with the classification certainty of
less than a threshold ThTr can be reported inconclusive and censored from the
medication detection report. Figure 2 displays one example of the change in the
percentage of inconclusive data with respect to thresholds 50% to 90% on the
classification certainty. We selected threshold ThTr for every training data such
that there was at most 1% rejection rate in the decision report. The threshold
ThTr along with the estimated parameters A and B were then used in the
testing phase.
2.5.2. Testing:
The selected features (from the above process) were extracted from the test-
ing data, and passed through the trained SVM model to obtain the decision
values (D1×NTe). Given that the medication state does not normally change so
quickly, rapid fluctuating outliers in the predicted decision values were adjusted
accordingly. A fuzzy labeling approach was used to adjust the classification la-
bel of every second data based on a group of its contiguous feature vectors. This
fuzzy labeling process was performed using two averaging filters. The first aver-
aging filter was applied to the decision values (D1×NTe). The filter had a width
of five steps and four-step overlap to reduce the effect of outliers in the contigu-
ous decision values that share part of the signal between each other. The output
of this filter was then furthered processed using a sliding 40-second averaging
filter. After filtering, the averaged decision values (M1×NTe) were used to pre-
dict the medication state of every window. The medication state was predicted
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Figure 2: The plot on the left side is a sample of Platt sigmoid and the plot on the right
side is the training accuracy corresponding to different threshold values on the classification
certainty. The percentages represent the inconclusive data for nine different threshold values
from 50% to 90%.
as medication OFF if Mn > zero, and otherwise it was predicted as medication
ON. The trained A and B parameters from the training phase were employed
to estimate the classification certainty for every second n. Eq. 6 was used for
medication OFF detection cases and Eq. 7 was used for cases with medication
ON detection. The trained threshold ThTr was used to select and report the
decision values with a high classification certainty value and the remaining data
with a certainty value of less than ThTr was reported as inconclusive.
3. Results
The developed medication state detection algorithm was trained and evalu-
ated using the dataset in Section 2.1. The feature selection and SVM training
process resulted in different SVM hyper-parameters and features for different
subjects. Linear kernel was selected for five individuals and RBF kernel for the
rest of them. Figure 3 shows the occurrence rate of the selected features among
all the subjects in our study. A occurrence rate of 100% means that that specific
feature provides a high medication ON/OFF discrimination and was selected for
all the subjects. The testing accuracy, sensitivity, and specificity results of all
the subjects are reported in Table 4. On average, there was 2.7% of inconclusive
data with an average classification accuracy of 90.5%, sensitivity of 94.2%, and
specificity of 85.4%.
A sample of the medication ON/OFF report that was predicted by the algo-
rithm is shown in Figure 4. The tall boxes indicate where a medication ON state
was predicated and the shorter boxes show a medication OFF prediction. The
red tracing provides the certainty measure of the SVM algorithm with respect to
the predicted medication state. A classification certainty of 1 indicates that the
SVM classifier makes a prediction with 100% certainty. As indicated by the red
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Figure 3: Occurrence rate of the selected features. The features’ numbers are as defined in
Table 3.
Table 4: Testing Results of ON/OFF Medication State Detection.
Subjects
Performance 1 2 3 4 5 6 7 8 9 10
Accuracy (%) 99.8 99.5 96.5 95.7 95.4 94.1 93.5 93.4 92.8 92.5
Sensitivity (%) 100 100 99.5 99.8 99.2 99.9 98.4 97.3 95.2 96.0
Specificity (%) 98.7 98.1 88.8 87.6 86.3 85.4 85.5 84.2 85.8 84.9
Subjects
Performance 11 12 13 14 15 16 17 18 19 Ave.
Accuracy (%) 90.7 89.3 87.4 86.5 85.6 85.2 84.7 79.8 77.3 90.5
Sensitivity (%) 92.1 91.0 88.2 92.3 86.4 88.9 88.3 89.4 88.5 94.2
Specificity (%) 86.3 85.9 86.3 79.1 84.9 82.7 81.9 76.5 74.2 85.4
tracing, the algorithm detected the medication states with a high certainty for
most of the times with the highest number of false detection occurring during
the transition from the OFF to ON state.
3.1. Classification Performance and Activity Type
Amediation state monitoring algorithm that can provide accurate and objec-
tive information about the duration in ON and OFF states has to continuously
detect medication ON/OFF states as the subjects perform a variety of daily rou-
tine activities. Here the developed algorithm was trained using data from four
activities (i.e., walking, resting, drinking, and dressing) and tested on a total of
seven activities consisting of four training activities (with no overlap between
the training and testing data) and three additional activities (i.e., brushing,
unpacking groceries, and cutting food). To evaluate the robustness of the devel-
oped algorithm to the activities that were not included in the classifier training
phase, we obtained the average testing accuracy of the algorithm for separate
activities (see Figure 5). The average accuracy for the group of activities in
the training phase was 91.3% and for the group of the new activities, it was
11
Figure 4: The classification results (1 medication OFF, 2 medication ON) with the certainty
(continuous line between 0 and 1) for subject 14.
88.4%. We performed a paired t-test between the average accuracy of the two
activity groups as well as the accuracy of all the 21 possible pairs of activities
(e.g., walking and brushing, resting and brushing, and etc.). These analyses did
not identify any statistically significant difference between classification perfor-
mance of any of the activities indicating that the algorithm was robust to the
new activities that were not used in the training phase.
Figure 5: Testing accuracy for different activities. The central mark indicates the median,
and the bottom and top edges of the box indicate the 25th and 75th percentiles, respectively.
The whiskers extend to the minimum and maximum data points.
3.2. Sensor Locations and Tremor
Fewer number of wearable sensors in a wearable-based mediation state mon-
itoring system can improve its user-acceptability and practicality. Hence, we
investigated if there was a relationship between the number and location of the
sensors and a disease symptom (here tremor) that can help to minimize the
number of sensors while achieving the highest classification accuracy. For this
purpose, we repeated the classification training and testing phase as described
12
Figure 6: Occurrence of the sensor combinations with the highest testing accuracy for three
symptom groups of no tremor, wrist tremor, and ankle tremor.
in Section 2.5, using only wrist sensor and only ankle sensor, and calculated the
testing accuracy for every subject. Next, the subjects were divided into three
symptom groups as diagnosed by the neurologist: without tremor (12 subjects),
with dominant tremor on wrist (4 subjects), and with dominant tremor on ankle
(3 subjects). We compared the classification accuracy (rounded to the nearest
one) of three sensor combinations (both wrist and ankle sensors, only wrist sen-
sor, and only ankle sensor) for every symptom group, and counted the number
of subjects with the highest accuracy when using a sensor combination. If one
subject had a highest classification accuracy using more than one of the sensor
combinations, we counted that subject towards all of those sensor combinations.
For example, considering the no-tremor group with 12 subjects, our finding was
as follows: Nine subjects had their highest accuracy using both wrist and ankle
sensors; however, one of these subjects resulted in an equally-well accuracy when
using only wrist sensor, and two of them achieved an equally-well accuracy when
using only ankle sensor. Three subjects achieved the best classification accuracy
only when wrist sensor was used, and three subjects resulted in their highest
classification accuracy only using ankle sensor. These results were counted as
4, 5, and 9 for the best performance using only wrist, only ankle, and both
wrist and ankle, respectively. The same process was repeated for the other two
symptom groups and the results are reported in Figure 6. One interesting ob-
servation from Figure 6 is that for all the subjects with ankle tremor, using only
ankle sensor was sufficient to achieve the highest classification performance.
4. Discussions
We developed a technology-based assessment of PD subjects’ medication
ON and OFF states, using data from two wearable sensors, to provide objec-
tive measures, instead of patient diary or self-report, that can be used by the
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treating physician to adjust therapy [6]. We developed a feature extraction and
selection algorithm based on SVM classifier with fuzzy labeling. Using concur-
rently recorded sensor data and gold-standard medication ON and OFF states
from 19 PD subjects, we tested our hypothesis that the medication ON and
OFF patterns in the data from two wearable sensors can be modeled and iden-
tified for every individual. Several interesting observations were made via our
analysis: First, our analysis supports our hypothesis by demonstrating that,
using the data from two sensors, the developed algorithm was able to predict
correct medication states with a high average accuracy of 90.5%, sensitivity of
94.2%, and specificity of 85.4% (Table 4). Moreover, the algorithm performs
equally-well for all the seven activities that were considered in this study (Fig-
ure 5). Since we trained the classifier using only part of the data from four of
the activities and tested for all the data, including three new activities (Table
2), this observation indicates that the algorithm successfully models the medi-
cation state patterns, and can potentially be used to detect medication states
during subjects’ daily routine activities.
Another interesting observation is that our analysis indicates that the ON/OFF-
discriminant features are different between subjects supporting the need for an
individualized classifier training approach verses a "one-size-fits-all" approach.
As shown in Figure 3, there is a difference in the set of features that are selected
for every subject and from each sensor. Most of the features were selected for
more than 70% of the subjects, but some of them (six of the wrist features and
two of the ankle features) were selected for less than 70% of the subjects. Dom-
inant "wrist features" with the occurrence of greater than 90% were the signal
power at frequencies > 4Hz [10], dominant frequency [23], and peak-to-peak of
the signal. The significant "ankle features" were the number of the autocorre-
lation peaks and the lag of the first autocorrelation peak. The average jerk and
mean features had the least occurrence and the cross-correlation feature was
informative only in the case of the ankle sensor.
We also investigated the possibility of using only one sensor for detecting
the medication ON/OFF states. For this purpose, we determined the sensor
combination that achieved the highest classification accuracy for every subject
and provided its distribution for the presence of tremor in the subject’s wrist
or ankle (Figure 6). Our analysis indicates that different sensor numbers and
placements provide different performances. It is interesting that using both
wrist and ankle sensors does not always result in the best performance. All
the three individuals with the most dominant tremor on their leg had the best
classification accuracy using only a single ankle sensor (see Figure 6) and three
(out of four) individuals with most dominant tremor on their hand had the
best classification accuracy using only a wrist sensor. This observation suggests
the possibility of a strategy in selecting the number and placement of sensors,
which is using only an ankle sensor for individuals with the most dominant
tremor on the leg and using an ankle and wrist sensor combination for the other
subjects. The reliability of such as sensor placement strategy has to be further
investigated in future work with higher number of subjects.
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Table 5: Comparison of Medication ON/OFF State Detection Methods
References # Sensors # Subjects
Data Duration
for Each Subject
Classification
Method
Activity-Independent
Model (Yes, No)
Individualized-Model
(Yes, No, Partial)
Results
Keijsers et al. [10]
One tri-axial
accelerometer
23 3 hours
Linear discriminant
and ANN
No
(excludes walking)
Partial (Tremor,
and non-tremor)
Sens.: 97%
Spec.: 97%
Sama et al. [9]
One tri-axial
accelerometer
20 1 hour
SVM and
linear discriminant
No (gait) No
Acc.: 94%, Sens.:
84%, Spec.: 90%
Perez-Lopez et al. [7]
One tri-axial
accelerometer
7 6 hours Linear discriminant
No (walking and
non-walking)
Partial (Threshold
on Bradykinesia )
Sens.: 99.9%
Spec.: 99.9%
Rodriguez-
Molinero et al. [8]
One tri-axial
accelerometer
35 1.4 - 5.5 hours Linear discriminant No (only walking) Yes
Sens.: 96%
Spec.: 94%
Khan et al. [12]
One tri-axial
accelerometer
12 1 hour SVM Yes No Acc.: 72%
Salarian et al. [13]
Five gyroscopes
and accelerometers
13
AC-UPDRS ≥ 16 3-6 hours Logistic regression Yes No
Sens.: 90%
Spec.: 76%
Hammerla et al. [35]
Two tri-axial
accelerometers
32
4 hours (in lab)
1 week (in home)
Restricted
Boltzmann Machines
Yes No
Mean f1-score:
68%
Fisher et al. [33]
Two tri-axial
accelerometers
32
4 hours (in lab)
1 week (in home)
ANN Yes No
Sens.: 55%
Spec.: 83%
Um et al. [34]
One
accelerometer
30 3-4 hours
Convolutional
Neural Networks
Yes No
Acc.: 63.1% for ON, OFF
and ON with dyskinesia
Hoff et al. [11]
Seven uni-axial
accelerometers
15 24 hours
Linear
discriminant
Yes Yes
Sens.: 60%-71%
Spec.: 66%-76%
Proposed Two tri-axial
gyroscopes
19 1 hour
SVM with fuzzy
classification
Yes Yes Acc.:91%, Sens.:
94%, Spec.: 85%
4.1. Comparison to Other Studies
A summary of the previous studies for the classification of PD medication
states is listed in Table 5. There are two main types of medication detection ap-
proached in the literature. One approach provide medication states only during
some specific activities, such as walking or non-walking, [10, 9, 7, 8]; however,
this approach is unable to provide a continuous monitoring of the subjects as
needed for detection of the duration of different medication states. The other
approach, similar to our algorithm, makes a medication state detection inde-
pendent of the activity type [12, 13, 14, 33, 11, 34], and hence is able to provide
duration in different medication states. Our developed algorithm provided the
highest sensitivity (94%) and specificity (85%) compared to the state-of-the-art
using only two sensors. The second-highest performance was achieved by the
work reported in Ref. [13] with a sensitivity of 90% and specificity of 76%,
using five sensors, for 13 subjects with an average change between the ON- and
OFF-state UPDRS (AC-UPDRS) ≥ 16. In our work, the average classification
performance for the subjects who had an AC-UPDRS ≥ 16 (eight out of 19
subjects) was 98% sensitivity and 90% specificity, which is significantly higher
that the reported performance in [13]. However, it is worth mentioning that
there is a high variability between the different studies in terms of the number
of sensors (range of one to seven), data duration (range of one hour to one week),
and subject numbers (range of 12 to 19), which makes it difficult to perform a
fair comparison between the methods.
4.2. Clinical Implications and Study Limitations
The developed algorithm has the potential to establish a wearable-based
mediation state monitoring system to provide objective measures, from the PD
subjects in free-living condition, that can be used by the treating physician to ad-
just therapy. We used an individualized approach to train a customized classifier
for every subjects. Similar to the other individualized approaches [8, 11, 10, 7],
our work uses labeled training data from the same subject, assuming that some
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gold-standard medication-state data is available for a subject. Given that the
focus of this study is the PD subjects with motor fluctuation who go through
frequent follow-up visit, we designed the classifier training phase based on a
short duration of training data from the activities (i.e., ambulation, drinking,
resting, and dressing) that can be easily performed in any clinical office. Hence,
once the algorithm is trained, it can be readily used as a passive system to moni-
tor medication fluctuations without relying on patient or physician engagement.
The algorithm was tested using sensor data as the subjects performed several
routine activities in a clinical lab setting. In our future work, we will investigate
the algorithm’s performance as the subjects perform a variety of activities in
their homes. We will also investigate the sensitivity of the algorithm to the
variations in the sensor placements when the subjects wear their own sensors at
home. Our analysis on selecting the number of sensors and their placement was
based on only the tremor symptom. The reliability of this selection to optimize
the number of required sensors will be studied using more subjects in our future
work.
5. Conclusion
In this paper, we developed a sensor-based assessment system that can con-
tinuously detect patients’ medication ON and OFF states as the patients per-
form different types of daily routine activities. A series of novel signal features
and feature selection approaches were proposed and integrated into an SVM
classifier with fuzzy labeling. The developed algorithm was assessed using data
from 19 PD subjects, and the results supported our hypothesis that it was pos-
sible to model and detect the subjects’ medication ON and OFF state patterns
from the data from two wearable sensors as the subjects perform different ac-
tivities. The proposed algorithm used data from only two sensors on wrist and
ankle, and it was able to detect the response to medication during subjects’ daily
routine activities with an average 90.5% accuracy 94.2% sensitivity, and 85.4%
specificity. The developed algorithm would enable a sensor-based assessment
system that can provide objective measures about the duration in medication
ON and OFF states that are obtained from patients’ self-reports. Such a system
could provide accurate and timely therapy adjustments in place of less reliable
patient self-reports, and as a result considerably improve both the care deliv-
ery and quality of life for the millions of patients afflicted by this debilitating
neurodegenerative disorder.
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